nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—lung cancer—kidney cancer	0.466	1	CtDrD
Pemetrexed—TYMS—Capecitabine—kidney cancer	0.103	0.319	CbGbCtD
Pemetrexed—SLC29A1—Gemcitabine—kidney cancer	0.0772	0.239	CbGbCtD
Pemetrexed—DCK—Gemcitabine—kidney cancer	0.0715	0.221	CbGbCtD
Pemetrexed—TYMS—Gemcitabine—kidney cancer	0.0715	0.221	CbGbCtD
Pemetrexed—GART—nephron tubule—kidney cancer	0.00209	0.0724	CbGeAlD
Pemetrexed—GART—renal system—kidney cancer	0.0019	0.0658	CbGeAlD
Pemetrexed—GART—kidney—kidney cancer	0.00184	0.0636	CbGeAlD
Pemetrexed—GART—cortex of kidney—kidney cancer	0.00179	0.062	CbGeAlD
Pemetrexed—GART—gonad—kidney cancer	0.00171	0.059	CbGeAlD
Pemetrexed—GART—cardiac atrium—kidney cancer	0.00171	0.0589	CbGeAlD
Pemetrexed—ATIC—renal system—kidney cancer	0.00129	0.0447	CbGeAlD
Pemetrexed—ATIC—kidney—kidney cancer	0.00125	0.0432	CbGeAlD
Pemetrexed—ATIC—gonad—kidney cancer	0.00116	0.0401	CbGeAlD
Pemetrexed—TYMS—nephron tubule—kidney cancer	0.000965	0.0333	CbGeAlD
Pemetrexed—DHFR—nephron tubule—kidney cancer	0.000955	0.033	CbGeAlD
Pemetrexed—DHFR—renal system—kidney cancer	0.000868	0.03	CbGeAlD
Pemetrexed—DHFR—kidney—kidney cancer	0.000839	0.029	CbGeAlD
Pemetrexed—DCK—nephron tubule—kidney cancer	0.000826	0.0286	CbGeAlD
Pemetrexed—TYMS—cortex of kidney—kidney cancer	0.000826	0.0285	CbGeAlD
Pemetrexed—DHFR—cortex of kidney—kidney cancer	0.000817	0.0282	CbGeAlD
Pemetrexed—ATIC—Everolimus—Temsirolimus—kidney cancer	0.000788	0.317	CbGdCrCtD
Pemetrexed—SLC29A1—renal system—kidney cancer	0.000786	0.0272	CbGeAlD
Pemetrexed—TYMS—gonad—kidney cancer	0.000786	0.0272	CbGeAlD
Pemetrexed—DHFR—gonad—kidney cancer	0.000779	0.0269	CbGeAlD
Pemetrexed—DHFR—cardiac atrium—kidney cancer	0.000778	0.0269	CbGeAlD
Pemetrexed—SLC29A1—kidney—kidney cancer	0.00076	0.0263	CbGeAlD
Pemetrexed—SLC29A1—cortex of kidney—kidney cancer	0.00074	0.0256	CbGeAlD
Pemetrexed—DCK—cortex of kidney—kidney cancer	0.000707	0.0244	CbGeAlD
Pemetrexed—SLC29A1—gonad—kidney cancer	0.000705	0.0244	CbGeAlD
Pemetrexed—SLC29A1—cardiac atrium—kidney cancer	0.000704	0.0243	CbGeAlD
Pemetrexed—DCK—gonad—kidney cancer	0.000674	0.0233	CbGeAlD
Pemetrexed—DCK—cardiac atrium—kidney cancer	0.000673	0.0232	CbGeAlD
Pemetrexed—TYMS—Docetaxel—Paclitaxel—kidney cancer	0.000328	0.132	CbGdCrCtD
Pemetrexed—DCK—Sirolimus—Everolimus—kidney cancer	0.000209	0.0841	CbGdCrCtD
Pemetrexed—DCK—Sirolimus—Temsirolimus—kidney cancer	0.000209	0.0841	CbGdCrCtD
Pemetrexed—TYMS—Sirolimus—Temsirolimus—kidney cancer	0.000158	0.0633	CbGdCrCtD
Pemetrexed—TYMS—Sirolimus—Everolimus—kidney cancer	0.000158	0.0633	CbGdCrCtD
Pemetrexed—TYMS—Gefitinib—Erlotinib—kidney cancer	0.000157	0.0631	CbGdCrCtD
Pemetrexed—TYMS—Vinorelbine—Vinblastine—kidney cancer	0.000105	0.0423	CbGdCrCtD
Pemetrexed—TYMS—Vinorelbine—Vincristine—kidney cancer	0.000105	0.0423	CbGdCrCtD
Pemetrexed—TYMS—Vincristine—Vinblastine—kidney cancer	9e-05	0.0361	CbGdCrCtD
Pemetrexed—TYMS—Vinblastine—Vincristine—kidney cancer	7.24e-05	0.0291	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—kidney cancer	6.74e-05	0.0271	CbGdCrCtD
Pemetrexed—Abdominal pain—Sorafenib—kidney cancer	5.59e-05	0.000467	CcSEcCtD
Pemetrexed—Body temperature increased—Sorafenib—kidney cancer	5.59e-05	0.000467	CcSEcCtD
Pemetrexed—Diarrhoea—Everolimus—kidney cancer	5.58e-05	0.000466	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Sunitinib—kidney cancer	5.57e-05	0.000465	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Capecitabine—kidney cancer	5.57e-05	0.000465	CcSEcCtD
Pemetrexed—Pruritus—Erlotinib—kidney cancer	5.57e-05	0.000465	CcSEcCtD
Pemetrexed—Fatigue—Dactinomycin—kidney cancer	5.56e-05	0.000464	CcSEcCtD
Pemetrexed—Pain—Dactinomycin—kidney cancer	5.51e-05	0.00046	CcSEcCtD
Pemetrexed—Agranulocytosis—Capecitabine—kidney cancer	5.49e-05	0.000459	CcSEcCtD
Pemetrexed—Anorexia—Vincristine—kidney cancer	5.49e-05	0.000459	CcSEcCtD
Pemetrexed—Dysgeusia—Paclitaxel—kidney cancer	5.49e-05	0.000458	CcSEcCtD
Pemetrexed—Anaphylactic shock—Gemcitabine—kidney cancer	5.46e-05	0.000456	CcSEcCtD
Pemetrexed—Oedema—Gemcitabine—kidney cancer	5.46e-05	0.000456	CcSEcCtD
Pemetrexed—Infection—Gemcitabine—kidney cancer	5.43e-05	0.000453	CcSEcCtD
Pemetrexed—Dizziness—Vinblastine—kidney cancer	5.41e-05	0.000452	CcSEcCtD
Pemetrexed—Dizziness—Everolimus—kidney cancer	5.39e-05	0.00045	CcSEcCtD
Pemetrexed—Body temperature increased—Sunitinib—kidney cancer	5.38e-05	0.00045	CcSEcCtD
Pemetrexed—Abdominal pain—Sunitinib—kidney cancer	5.38e-05	0.00045	CcSEcCtD
Pemetrexed—Diarrhoea—Erlotinib—kidney cancer	5.38e-05	0.000449	CcSEcCtD
Pemetrexed—Nervous system disorder—Gemcitabine—kidney cancer	5.36e-05	0.000447	CcSEcCtD
Pemetrexed—Thrombocytopenia—Gemcitabine—kidney cancer	5.35e-05	0.000447	CcSEcCtD
Pemetrexed—Renal failure acute—Doxorubicin—kidney cancer	5.33e-05	0.000445	CcSEcCtD
Pemetrexed—Skin disorder—Gemcitabine—kidney cancer	5.31e-05	0.000443	CcSEcCtD
Pemetrexed—Hepatitis—Capecitabine—kidney cancer	5.28e-05	0.000441	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Dactinomycin—kidney cancer	5.27e-05	0.00044	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Vincristine—kidney cancer	5.25e-05	0.000438	CcSEcCtD
Pemetrexed—Pharyngitis—Capecitabine—kidney cancer	5.24e-05	0.000438	CcSEcCtD
Pemetrexed—Urinary tract disorder—Capecitabine—kidney cancer	5.22e-05	0.000436	CcSEcCtD
Pemetrexed—Hypersensitivity—Sorafenib—kidney cancer	5.21e-05	0.000435	CcSEcCtD
Pemetrexed—Anorexia—Gemcitabine—kidney cancer	5.21e-05	0.000435	CcSEcCtD
Pemetrexed—Vomiting—Vinblastine—kidney cancer	5.2e-05	0.000435	CcSEcCtD
Pemetrexed—Dizziness—Erlotinib—kidney cancer	5.2e-05	0.000434	CcSEcCtD
Pemetrexed—Vomiting—Everolimus—kidney cancer	5.18e-05	0.000433	CcSEcCtD
Pemetrexed—Anaemia—Paclitaxel—kidney cancer	5.18e-05	0.000433	CcSEcCtD
Pemetrexed—Urethral disorder—Capecitabine—kidney cancer	5.18e-05	0.000433	CcSEcCtD
Pemetrexed—Rash—Everolimus—kidney cancer	5.14e-05	0.000429	CcSEcCtD
Pemetrexed—Dermatitis—Everolimus—kidney cancer	5.14e-05	0.000429	CcSEcCtD
Pemetrexed—Abdominal pain—Dactinomycin—kidney cancer	5.1e-05	0.000426	CcSEcCtD
Pemetrexed—Body temperature increased—Dactinomycin—kidney cancer	5.1e-05	0.000426	CcSEcCtD
Pemetrexed—Asthenia—Sorafenib—kidney cancer	5.08e-05	0.000424	CcSEcCtD
Pemetrexed—Syncope—Paclitaxel—kidney cancer	5.03e-05	0.00042	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—kidney cancer	5.02e-05	0.00042	CcSEcCtD
Pemetrexed—Leukopenia—Paclitaxel—kidney cancer	5.02e-05	0.000419	CcSEcCtD
Pemetrexed—Hypersensitivity—Sunitinib—kidney cancer	5.02e-05	0.000419	CcSEcCtD
Pemetrexed—Decreased appetite—Vincristine—kidney cancer	5.01e-05	0.000418	CcSEcCtD
Pemetrexed—Pruritus—Sorafenib—kidney cancer	5.01e-05	0.000418	CcSEcCtD
Pemetrexed—Vomiting—Erlotinib—kidney cancer	5e-05	0.000418	CcSEcCtD
Pemetrexed—Erythema multiforme—Capecitabine—kidney cancer	5e-05	0.000417	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Gemcitabine—kidney cancer	4.98e-05	0.000416	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Vincristine—kidney cancer	4.97e-05	0.000415	CcSEcCtD
Pemetrexed—Fatigue—Vincristine—kidney cancer	4.97e-05	0.000415	CcSEcCtD
Pemetrexed—Rash—Erlotinib—kidney cancer	4.96e-05	0.000414	CcSEcCtD
Pemetrexed—Dermatitis—Erlotinib—kidney cancer	4.96e-05	0.000414	CcSEcCtD
Pemetrexed—Eye disorder—Capecitabine—kidney cancer	4.94e-05	0.000412	CcSEcCtD
Pemetrexed—Loss of consciousness—Paclitaxel—kidney cancer	4.93e-05	0.000411	CcSEcCtD
Pemetrexed—Pain—Vincristine—kidney cancer	4.93e-05	0.000411	CcSEcCtD
Pemetrexed—Constipation—Vincristine—kidney cancer	4.93e-05	0.000411	CcSEcCtD
Pemetrexed—Asthenia—Sunitinib—kidney cancer	4.89e-05	0.000408	CcSEcCtD
Pemetrexed—Dyspnoea—Gemcitabine—kidney cancer	4.87e-05	0.000407	CcSEcCtD
Pemetrexed—Nausea—Vinblastine—kidney cancer	4.86e-05	0.000406	CcSEcCtD
Pemetrexed—Nausea—Everolimus—kidney cancer	4.84e-05	0.000404	CcSEcCtD
Pemetrexed—Diarrhoea—Sorafenib—kidney cancer	4.84e-05	0.000404	CcSEcCtD
Pemetrexed—Hypertension—Paclitaxel—kidney cancer	4.84e-05	0.000404	CcSEcCtD
Pemetrexed—Pruritus—Sunitinib—kidney cancer	4.82e-05	0.000402	CcSEcCtD
Pemetrexed—Arthralgia—Paclitaxel—kidney cancer	4.77e-05	0.000399	CcSEcCtD
Pemetrexed—Chest pain—Paclitaxel—kidney cancer	4.77e-05	0.000399	CcSEcCtD
Pemetrexed—Myalgia—Paclitaxel—kidney cancer	4.77e-05	0.000399	CcSEcCtD
Pemetrexed—Decreased appetite—Gemcitabine—kidney cancer	4.75e-05	0.000397	CcSEcCtD
Pemetrexed—Hypersensitivity—Dactinomycin—kidney cancer	4.75e-05	0.000397	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	4.74e-05	0.000396	CcSEcCtD
Pemetrexed—Arrhythmia—Capecitabine—kidney cancer	4.72e-05	0.000394	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Gemcitabine—kidney cancer	4.72e-05	0.000394	CcSEcCtD
Pemetrexed—Fatigue—Gemcitabine—kidney cancer	4.71e-05	0.000393	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Vincristine—kidney cancer	4.71e-05	0.000393	CcSEcCtD
Pemetrexed—Dizziness—Sorafenib—kidney cancer	4.68e-05	0.000391	CcSEcCtD
Pemetrexed—Constipation—Gemcitabine—kidney cancer	4.67e-05	0.00039	CcSEcCtD
Pemetrexed—Pain—Gemcitabine—kidney cancer	4.67e-05	0.00039	CcSEcCtD
Pemetrexed—Nausea—Erlotinib—kidney cancer	4.67e-05	0.00039	CcSEcCtD
Pemetrexed—Alopecia—Capecitabine—kidney cancer	4.67e-05	0.00039	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—kidney cancer	4.66e-05	0.00039	CcSEcCtD
Pemetrexed—Diarrhoea—Sunitinib—kidney cancer	4.66e-05	0.000389	CcSEcCtD
Pemetrexed—Asthenia—Dactinomycin—kidney cancer	4.63e-05	0.000386	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—kidney cancer	4.61e-05	0.000385	CcSEcCtD
Pemetrexed—Malnutrition—Capecitabine—kidney cancer	4.6e-05	0.000384	CcSEcCtD
Pemetrexed—Erythema—Capecitabine—kidney cancer	4.6e-05	0.000384	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—kidney cancer	4.58e-05	0.000382	CcSEcCtD
Pemetrexed—Anaphylactic shock—Paclitaxel—kidney cancer	4.57e-05	0.000382	CcSEcCtD
Pemetrexed—Oedema—Paclitaxel—kidney cancer	4.57e-05	0.000382	CcSEcCtD
Pemetrexed—Abdominal pain—Vincristine—kidney cancer	4.55e-05	0.00038	CcSEcCtD
Pemetrexed—Body temperature increased—Vincristine—kidney cancer	4.55e-05	0.00038	CcSEcCtD
Pemetrexed—Infection—Paclitaxel—kidney cancer	4.54e-05	0.00038	CcSEcCtD
Pemetrexed—Dysgeusia—Capecitabine—kidney cancer	4.5e-05	0.000376	CcSEcCtD
Pemetrexed—Dizziness—Sunitinib—kidney cancer	4.5e-05	0.000376	CcSEcCtD
Pemetrexed—Shock—Paclitaxel—kidney cancer	4.5e-05	0.000376	CcSEcCtD
Pemetrexed—Vomiting—Sorafenib—kidney cancer	4.5e-05	0.000376	CcSEcCtD
Pemetrexed—Nervous system disorder—Paclitaxel—kidney cancer	4.49e-05	0.000375	CcSEcCtD
Pemetrexed—Thrombocytopenia—Paclitaxel—kidney cancer	4.48e-05	0.000374	CcSEcCtD
Pemetrexed—Rash—Sorafenib—kidney cancer	4.46e-05	0.000373	CcSEcCtD
Pemetrexed—Dermatitis—Sorafenib—kidney cancer	4.46e-05	0.000372	CcSEcCtD
Pemetrexed—Skin disorder—Paclitaxel—kidney cancer	4.44e-05	0.000371	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	4.43e-05	0.00037	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.43e-05	0.00037	CcSEcCtD
Pemetrexed—Diarrhoea—Dactinomycin—kidney cancer	4.41e-05	0.000368	CcSEcCtD
Pemetrexed—Anorexia—Paclitaxel—kidney cancer	4.36e-05	0.000364	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—kidney cancer	4.34e-05	0.000363	CcSEcCtD
Pemetrexed—Vomiting—Sunitinib—kidney cancer	4.33e-05	0.000362	CcSEcCtD
Pemetrexed—Body temperature increased—Gemcitabine—kidney cancer	4.32e-05	0.000361	CcSEcCtD
Pemetrexed—Rash—Sunitinib—kidney cancer	4.29e-05	0.000359	CcSEcCtD
Pemetrexed—Dermatitis—Sunitinib—kidney cancer	4.29e-05	0.000358	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—kidney cancer	4.26e-05	0.000355	CcSEcCtD
Pemetrexed—Anaemia—Capecitabine—kidney cancer	4.25e-05	0.000355	CcSEcCtD
Pemetrexed—Hypersensitivity—Vincristine—kidney cancer	4.24e-05	0.000354	CcSEcCtD
Pemetrexed—TYMS—Azacitidine—Gemcitabine—kidney cancer	4.24e-05	0.017	CbGdCrCtD
Pemetrexed—Nausea—Sorafenib—kidney cancer	4.2e-05	0.000351	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—kidney cancer	4.17e-05	0.000348	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.17e-05	0.000348	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—kidney cancer	4.15e-05	0.000346	CcSEcCtD
Pemetrexed—Asthenia—Vincristine—kidney cancer	4.13e-05	0.000345	CcSEcCtD
Pemetrexed—Syncope—Capecitabine—kidney cancer	4.13e-05	0.000345	CcSEcCtD
Pemetrexed—Leukopenia—Capecitabine—kidney cancer	4.12e-05	0.000344	CcSEcCtD
Pemetrexed—Vomiting—Dactinomycin—kidney cancer	4.1e-05	0.000342	CcSEcCtD
Pemetrexed—Dyspnoea—Paclitaxel—kidney cancer	4.08e-05	0.000341	CcSEcCtD
Pemetrexed—Rash—Dactinomycin—kidney cancer	4.06e-05	0.000339	CcSEcCtD
Pemetrexed—Nausea—Sunitinib—kidney cancer	4.04e-05	0.000338	CcSEcCtD
Pemetrexed—Loss of consciousness—Capecitabine—kidney cancer	4.04e-05	0.000338	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—kidney cancer	4.04e-05	0.000338	CcSEcCtD
Pemetrexed—Dyspepsia—Paclitaxel—kidney cancer	4.03e-05	0.000336	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—kidney cancer	3.98e-05	0.000332	CcSEcCtD
Pemetrexed—Decreased appetite—Paclitaxel—kidney cancer	3.98e-05	0.000332	CcSEcCtD
Pemetrexed—Hypertension—Capecitabine—kidney cancer	3.97e-05	0.000332	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Paclitaxel—kidney cancer	3.95e-05	0.00033	CcSEcCtD
Pemetrexed—Fatigue—Paclitaxel—kidney cancer	3.94e-05	0.000329	CcSEcCtD
Pemetrexed—Diarrhoea—Vincristine—kidney cancer	3.94e-05	0.000329	CcSEcCtD
Pemetrexed—Asthenia—Gemcitabine—kidney cancer	3.92e-05	0.000327	CcSEcCtD
Pemetrexed—Myalgia—Capecitabine—kidney cancer	3.92e-05	0.000327	CcSEcCtD
Pemetrexed—Arthralgia—Capecitabine—kidney cancer	3.92e-05	0.000327	CcSEcCtD
Pemetrexed—Chest pain—Capecitabine—kidney cancer	3.92e-05	0.000327	CcSEcCtD
Pemetrexed—Pain—Paclitaxel—kidney cancer	3.91e-05	0.000327	CcSEcCtD
Pemetrexed—Constipation—Paclitaxel—kidney cancer	3.91e-05	0.000327	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PTGS1—kidney cancer	3.91e-05	0.000664	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.89e-05	0.000325	CcSEcCtD
Pemetrexed—DCK—Metabolism—ALAD—kidney cancer	3.87e-05	0.000657	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	3.87e-05	0.000657	CbGpPWpGaD
Pemetrexed—Pruritus—Gemcitabine—kidney cancer	3.87e-05	0.000323	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PSMD7—kidney cancer	3.83e-05	0.000651	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GSTM1—kidney cancer	3.83e-05	0.000651	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CRABP1—kidney cancer	3.83e-05	0.000651	CbGpPWpGaD
Pemetrexed—Nausea—Dactinomycin—kidney cancer	3.83e-05	0.00032	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—MYC—kidney cancer	3.82e-05	0.000649	CbGpPWpGaD
Pemetrexed—Dizziness—Vincristine—kidney cancer	3.81e-05	0.000318	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—kidney cancer	3.79e-05	0.000317	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—kidney cancer	3.79e-05	0.000317	CcSEcCtD
Pemetrexed—DCK—Metabolism—ST3GAL2—kidney cancer	3.78e-05	0.000642	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CCBL1—kidney cancer	3.78e-05	0.000642	CbGpPWpGaD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.76e-05	0.000314	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	3.76e-05	0.000638	CbGpPWpGaD
Pemetrexed—Oedema—Capecitabine—kidney cancer	3.75e-05	0.000314	CcSEcCtD
Pemetrexed—DHFR—Metabolism—GLIPR1—kidney cancer	3.75e-05	0.000637	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPAT—kidney cancer	3.75e-05	0.000637	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Paclitaxel—kidney cancer	3.74e-05	0.000312	CcSEcCtD
Pemetrexed—Diarrhoea—Gemcitabine—kidney cancer	3.74e-05	0.000312	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—kidney cancer	3.73e-05	0.000311	CcSEcCtD
Pemetrexed—Infection—Capecitabine—kidney cancer	3.73e-05	0.000311	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—PSMD7—kidney cancer	3.73e-05	0.000633	CbGpPWpGaD
Pemetrexed—Neuropathy peripheral—Doxorubicin—kidney cancer	3.72e-05	0.000311	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—kidney cancer	3.7e-05	0.000309	CcSEcCtD
Pemetrexed—Shock—Capecitabine—kidney cancer	3.69e-05	0.000308	CcSEcCtD
Pemetrexed—DCK—Metabolism—ALDH1A1—kidney cancer	3.69e-05	0.000627	CbGpPWpGaD
Pemetrexed—Conjunctivitis—Doxorubicin—kidney cancer	3.69e-05	0.000308	CcSEcCtD
Pemetrexed—Nervous system disorder—Capecitabine—kidney cancer	3.68e-05	0.000307	CcSEcCtD
Pemetrexed—Thrombocytopenia—Capecitabine—kidney cancer	3.68e-05	0.000307	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1B—kidney cancer	3.67e-05	0.000624	CbGpPWpGaD
Pemetrexed—Vomiting—Vincristine—kidney cancer	3.66e-05	0.000306	CcSEcCtD
Pemetrexed—Skin disorder—Capecitabine—kidney cancer	3.65e-05	0.000305	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PSMD7—kidney cancer	3.64e-05	0.000618	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—BCHE—kidney cancer	3.64e-05	0.000618	CbGpPWpGaD
Pemetrexed—GART—Metabolism—CYP1A1—kidney cancer	3.64e-05	0.000618	CbGpPWpGaD
Pemetrexed—Urticaria—Paclitaxel—kidney cancer	3.63e-05	0.000304	CcSEcCtD
Pemetrexed—Rash—Vincristine—kidney cancer	3.63e-05	0.000303	CcSEcCtD
Pemetrexed—Dermatitis—Vincristine—kidney cancer	3.63e-05	0.000303	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—AURKA—kidney cancer	3.63e-05	0.000616	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ST3GAL2—kidney cancer	3.62e-05	0.000616	CbGpPWpGaD
Pemetrexed—Abdominal pain—Paclitaxel—kidney cancer	3.62e-05	0.000302	CcSEcCtD
Pemetrexed—Body temperature increased—Paclitaxel—kidney cancer	3.62e-05	0.000302	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	3.61e-05	0.000613	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—SLC5A5—kidney cancer	3.59e-05	0.00061	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Doxorubicin—kidney cancer	3.59e-05	0.0003	CcSEcCtD
Pemetrexed—Anorexia—Capecitabine—kidney cancer	3.58e-05	0.000299	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PSMD7—kidney cancer	3.57e-05	0.000606	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ITPR2—kidney cancer	3.57e-05	0.000606	CbGpPWpGaD
Pemetrexed—Agranulocytosis—Doxorubicin—kidney cancer	3.54e-05	0.000296	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—AURKA—kidney cancer	3.54e-05	0.000601	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SLC5A3—kidney cancer	3.54e-05	0.000601	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PGK1—kidney cancer	3.54e-05	0.000601	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—kidney cancer	3.5e-05	0.000595	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—APRT—kidney cancer	3.49e-05	0.000593	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—FH—kidney cancer	3.49e-05	0.000593	CbGpPWpGaD
Pemetrexed—Vomiting—Gemcitabine—kidney cancer	3.47e-05	0.00029	CcSEcCtD
Pemetrexed—DCK—Metabolism—LDHB—kidney cancer	3.47e-05	0.00059	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—SLC2A1—kidney cancer	3.47e-05	0.000589	CbGpPWpGaD
Pemetrexed—Rash—Gemcitabine—kidney cancer	3.45e-05	0.000288	CcSEcCtD
Pemetrexed—Dermatitis—Gemcitabine—kidney cancer	3.44e-05	0.000287	CcSEcCtD
Pemetrexed—Nausea—Vincristine—kidney cancer	3.42e-05	0.000286	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.42e-05	0.000286	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—kidney cancer	3.41e-05	0.000284	CcSEcCtD
Pemetrexed—DHFR—Disease—PGK1—kidney cancer	3.4e-05	0.000577	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SLC5A3—kidney cancer	3.4e-05	0.000577	CbGpPWpGaD
Pemetrexed—Pharyngitis—Doxorubicin—kidney cancer	3.38e-05	0.000282	CcSEcCtD
Pemetrexed—Hypersensitivity—Paclitaxel—kidney cancer	3.37e-05	0.000281	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—kidney cancer	3.36e-05	0.000281	CcSEcCtD
Pemetrexed—Dyspnoea—Capecitabine—kidney cancer	3.35e-05	0.00028	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—kidney cancer	3.34e-05	0.000279	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—MYC—kidney cancer	3.33e-05	0.000566	CbGpPWpGaD
Pemetrexed—DHFR—Disease—LDHB—kidney cancer	3.33e-05	0.000566	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SFRP2—kidney cancer	3.33e-05	0.000566	CbGpPWpGaD
Pemetrexed—Dyspepsia—Capecitabine—kidney cancer	3.3e-05	0.000276	CcSEcCtD
Pemetrexed—Asthenia—Paclitaxel—kidney cancer	3.28e-05	0.000274	CcSEcCtD
Pemetrexed—DHFR—Metabolism—GPC3—kidney cancer	3.28e-05	0.000557	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	3.28e-05	0.000557	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GLIPR1—kidney cancer	3.27e-05	0.000556	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPAT—kidney cancer	3.27e-05	0.000556	CbGpPWpGaD
Pemetrexed—Decreased appetite—Capecitabine—kidney cancer	3.26e-05	0.000273	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—PSMD7—kidney cancer	3.25e-05	0.000553	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ACHE—kidney cancer	3.25e-05	0.000552	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTT1—kidney cancer	3.25e-05	0.000552	CbGpPWpGaD
Pemetrexed—Nausea—Gemcitabine—kidney cancer	3.25e-05	0.000271	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Capecitabine—kidney cancer	3.24e-05	0.000271	CcSEcCtD
Pemetrexed—Fatigue—Capecitabine—kidney cancer	3.24e-05	0.00027	CcSEcCtD
Pemetrexed—Pruritus—Paclitaxel—kidney cancer	3.24e-05	0.00027	CcSEcCtD
Pemetrexed—SLC46A1—Disease—SLC2A1—kidney cancer	3.23e-05	0.000548	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Doxorubicin—kidney cancer	3.22e-05	0.000269	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—kidney cancer	3.22e-05	0.000547	CbGpPWpGaD
Pemetrexed—Constipation—Capecitabine—kidney cancer	3.21e-05	0.000268	CcSEcCtD
Pemetrexed—Pain—Capecitabine—kidney cancer	3.21e-05	0.000268	CcSEcCtD
Pemetrexed—SLC46A1—Disease—JUNB—kidney cancer	3.2e-05	0.000544	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CA2—kidney cancer	3.19e-05	0.000542	CbGpPWpGaD
Pemetrexed—Eye disorder—Doxorubicin—kidney cancer	3.18e-05	0.000266	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—AURKA—kidney cancer	3.16e-05	0.000538	CbGpPWpGaD
Pemetrexed—Diarrhoea—Paclitaxel—kidney cancer	3.13e-05	0.000261	CcSEcCtD
Pemetrexed—DHFR—Metabolism—ALAD—kidney cancer	3.11e-05	0.000528	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TCEB1—kidney cancer	3.11e-05	0.000528	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TCEB2—kidney cancer	3.11e-05	0.000528	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—SCARB1—kidney cancer	3.08e-05	0.000523	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Capecitabine—kidney cancer	3.07e-05	0.000256	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2B—kidney cancer	3.05e-05	0.000518	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS1—kidney cancer	3.05e-05	0.000517	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—FH—kidney cancer	3.04e-05	0.000517	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—APRT—kidney cancer	3.04e-05	0.000517	CbGpPWpGaD
Pemetrexed—Arrhythmia—Doxorubicin—kidney cancer	3.04e-05	0.000254	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	3.04e-05	0.000516	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ST3GAL2—kidney cancer	3.04e-05	0.000516	CbGpPWpGaD
Pemetrexed—Dizziness—Paclitaxel—kidney cancer	3.03e-05	0.000253	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—kidney cancer	3.01e-05	0.000251	CcSEcCtD
Pemetrexed—DCK—Metabolism—CA9—kidney cancer	3.01e-05	0.000511	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	3e-05	0.00051	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PSMD7—kidney cancer	2.99e-05	0.000507	CbGpPWpGaD
Pemetrexed—Urticaria—Capecitabine—kidney cancer	2.98e-05	0.000249	CcSEcCtD
Pemetrexed—Abdominal pain—Capecitabine—kidney cancer	2.97e-05	0.000248	CcSEcCtD
Pemetrexed—Body temperature increased—Capecitabine—kidney cancer	2.97e-05	0.000248	CcSEcCtD
Pemetrexed—DHFR—Metabolism—ALDH1A1—kidney cancer	2.97e-05	0.000504	CbGpPWpGaD
Pemetrexed—Erythema—Doxorubicin—kidney cancer	2.97e-05	0.000248	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—kidney cancer	2.97e-05	0.000248	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	2.94e-05	0.000499	CbGpPWpGaD
Pemetrexed—Vomiting—Paclitaxel—kidney cancer	2.91e-05	0.000243	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—kidney cancer	2.9e-05	0.000242	CcSEcCtD
Pemetrexed—ATIC—Metabolism—GSTP1—kidney cancer	2.89e-05	0.000491	CbGpPWpGaD
Pemetrexed—Rash—Paclitaxel—kidney cancer	2.88e-05	0.000241	CcSEcCtD
Pemetrexed—Dermatitis—Paclitaxel—kidney cancer	2.88e-05	0.000241	CcSEcCtD
Pemetrexed—TYMS—Metabolism—GPC3—kidney cancer	2.86e-05	0.000486	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PGK1—kidney cancer	2.84e-05	0.000483	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC5A3—kidney cancer	2.84e-05	0.000483	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—BCHE—kidney cancer	2.83e-05	0.000481	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—kidney cancer	2.81e-05	0.000477	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—SLC5A5—kidney cancer	2.8e-05	0.000475	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—LDHB—kidney cancer	2.79e-05	0.000474	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CA2—kidney cancer	2.78e-05	0.000473	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	2.78e-05	0.000473	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Capecitabine—kidney cancer	2.77e-05	0.000231	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—BRCA2—kidney cancer	2.75e-05	0.000467	CbGpPWpGaD
Pemetrexed—Anaemia—Doxorubicin—kidney cancer	2.74e-05	0.000229	CcSEcCtD
Pemetrexed—ATIC—Metabolism—ABCB1—kidney cancer	2.74e-05	0.000465	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2B—kidney cancer	2.72e-05	0.000463	CbGpPWpGaD
Pemetrexed—Nausea—Paclitaxel—kidney cancer	2.72e-05	0.000227	CcSEcCtD
Pemetrexed—TYMS—Metabolism—ALAD—kidney cancer	2.71e-05	0.000461	CbGpPWpGaD
Pemetrexed—GART—Metabolism—POMC—kidney cancer	2.71e-05	0.00046	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—SLC2A1—kidney cancer	2.7e-05	0.000459	CbGpPWpGaD
Pemetrexed—Asthenia—Capecitabine—kidney cancer	2.69e-05	0.000225	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—kidney cancer	2.66e-05	0.000222	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2B—kidney cancer	2.66e-05	0.000452	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GSTM1—kidney cancer	2.66e-05	0.000452	CbGpPWpGaD
Pemetrexed—Pruritus—Capecitabine—kidney cancer	2.66e-05	0.000222	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—kidney cancer	2.65e-05	0.000222	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	2.65e-05	0.000451	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ST3GAL2—kidney cancer	2.65e-05	0.00045	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	2.65e-05	0.00045	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—BIRC5—kidney cancer	2.63e-05	0.000447	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	2.63e-05	0.000446	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN2B—kidney cancer	2.61e-05	0.000443	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Doxorubicin—kidney cancer	2.61e-05	0.000218	CcSEcCtD
Pemetrexed—TYMS—Metabolism—ALDH1A1—kidney cancer	2.59e-05	0.00044	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.58e-05	0.000438	CbGpPWpGaD
Pemetrexed—Diarrhoea—Capecitabine—kidney cancer	2.57e-05	0.000215	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	2.56e-05	0.000435	CbGpPWpGaD
Pemetrexed—Hypertension—Doxorubicin—kidney cancer	2.56e-05	0.000214	CcSEcCtD
Pemetrexed—DCK—Metabolism—CRABP1—kidney cancer	2.56e-05	0.000435	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—JUN—kidney cancer	2.54e-05	0.000432	CbGpPWpGaD
Pemetrexed—Myalgia—Doxorubicin—kidney cancer	2.52e-05	0.000211	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—kidney cancer	2.52e-05	0.000211	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—kidney cancer	2.52e-05	0.000211	CcSEcCtD
Pemetrexed—DHFR—Disease—RPL14—kidney cancer	2.52e-05	0.000429	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYP1A1—kidney cancer	2.52e-05	0.000428	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.51e-05	0.000209	CcSEcCtD
Pemetrexed—Dizziness—Capecitabine—kidney cancer	2.48e-05	0.000207	CcSEcCtD
Pemetrexed—TYMS—Metabolism—PGK1—kidney cancer	2.48e-05	0.000422	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC5A3—kidney cancer	2.48e-05	0.000422	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—PTEN—kidney cancer	2.46e-05	0.000418	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—LDHB—kidney cancer	2.43e-05	0.000413	CbGpPWpGaD
Pemetrexed—Oedema—Doxorubicin—kidney cancer	2.42e-05	0.000202	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—kidney cancer	2.42e-05	0.000202	CcSEcCtD
Pemetrexed—DHFR—Metabolism—CA9—kidney cancer	2.42e-05	0.000411	CbGpPWpGaD
Pemetrexed—Infection—Doxorubicin—kidney cancer	2.4e-05	0.000201	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—BRCA2—kidney cancer	2.4e-05	0.000407	CbGpPWpGaD
Pemetrexed—Vomiting—Capecitabine—kidney cancer	2.39e-05	0.000199	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—kidney cancer	2.38e-05	0.000199	CcSEcCtD
Pemetrexed—DCK—Metabolism—ITPR2—kidney cancer	2.38e-05	0.000404	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2B—kidney cancer	2.38e-05	0.000404	CbGpPWpGaD
Pemetrexed—Nervous system disorder—Doxorubicin—kidney cancer	2.37e-05	0.000198	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—kidney cancer	2.37e-05	0.000198	CcSEcCtD
Pemetrexed—Rash—Capecitabine—kidney cancer	2.37e-05	0.000198	CcSEcCtD
Pemetrexed—Dermatitis—Capecitabine—kidney cancer	2.36e-05	0.000197	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—BIRC5—kidney cancer	2.35e-05	0.000399	CbGpPWpGaD
Pemetrexed—Skin disorder—Doxorubicin—kidney cancer	2.35e-05	0.000196	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	2.31e-05	0.000393	CbGpPWpGaD
Pemetrexed—Anorexia—Doxorubicin—kidney cancer	2.31e-05	0.000193	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—BIRC5—kidney cancer	2.29e-05	0.00039	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ITPR2—kidney cancer	2.28e-05	0.000388	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTP1—kidney cancer	2.25e-05	0.000383	CbGpPWpGaD
Pemetrexed—Nausea—Capecitabine—kidney cancer	2.23e-05	0.000186	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.2e-05	0.000184	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	2.19e-05	0.000372	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTT1—kidney cancer	2.17e-05	0.000368	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ACHE—kidney cancer	2.17e-05	0.000368	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTGS2—kidney cancer	2.16e-05	0.000367	CbGpPWpGaD
Pemetrexed—Dyspnoea—Doxorubicin—kidney cancer	2.16e-05	0.00018	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—ABCB1—kidney cancer	2.13e-05	0.000362	CbGpPWpGaD
Pemetrexed—Dyspepsia—Doxorubicin—kidney cancer	2.13e-05	0.000178	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	2.13e-05	0.000362	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CA9—kidney cancer	2.11e-05	0.000358	CbGpPWpGaD
Pemetrexed—Decreased appetite—Doxorubicin—kidney cancer	2.1e-05	0.000176	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.09e-05	0.000174	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—kidney cancer	2.09e-05	0.000174	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HIF1A—kidney cancer	2.08e-05	0.000354	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	2.08e-05	0.000354	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TSC2—kidney cancer	2.08e-05	0.000353	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTM1—kidney cancer	2.07e-05	0.000352	CbGpPWpGaD
Pemetrexed—Pain—Doxorubicin—kidney cancer	2.07e-05	0.000173	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—kidney cancer	2.07e-05	0.000173	CcSEcCtD
Pemetrexed—DHFR—Metabolism—CRABP1—kidney cancer	2.06e-05	0.000349	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SCARB1—kidney cancer	2.05e-05	0.000349	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—BIRC5—kidney cancer	2.05e-05	0.000349	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—RAF1—kidney cancer	2.04e-05	0.000347	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS1—kidney cancer	2.03e-05	0.000345	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PSMD7—kidney cancer	1.99e-05	0.000339	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Doxorubicin—kidney cancer	1.98e-05	0.000165	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.97e-05	0.000334	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYP1A1—kidney cancer	1.96e-05	0.000333	CbGpPWpGaD
Pemetrexed—Urticaria—Doxorubicin—kidney cancer	1.92e-05	0.000161	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—kidney cancer	1.91e-05	0.00016	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—kidney cancer	1.91e-05	0.00016	CcSEcCtD
Pemetrexed—DHFR—Disease—PSMD7—kidney cancer	1.91e-05	0.000325	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ITPR2—kidney cancer	1.91e-05	0.000325	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—BCHE—kidney cancer	1.89e-05	0.000321	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTEN—kidney cancer	1.89e-05	0.00032	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—POMC—kidney cancer	1.88e-05	0.000319	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SLC5A5—kidney cancer	1.87e-05	0.000317	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—APC—kidney cancer	1.84e-05	0.000312	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KIT—kidney cancer	1.84e-05	0.000312	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.81e-05	0.000307	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—SLC2A1—kidney cancer	1.8e-05	0.000306	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CRABP1—kidney cancer	1.79e-05	0.000305	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Doxorubicin—kidney cancer	1.78e-05	0.000149	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.75e-05	0.000297	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ACHE—kidney cancer	1.74e-05	0.000296	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTT1—kidney cancer	1.74e-05	0.000296	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2A—kidney cancer	1.74e-05	0.000296	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—kidney cancer	1.74e-05	0.000145	CcSEcCtD
Pemetrexed—DHFR—Disease—SLC2A1—kidney cancer	1.73e-05	0.000294	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—BRAF—kidney cancer	1.73e-05	0.000293	CbGpPWpGaD
Pemetrexed—DHFR—Disease—JUNB—kidney cancer	1.72e-05	0.000292	CbGpPWpGaD
Pemetrexed—Pruritus—Doxorubicin—kidney cancer	1.71e-05	0.000143	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—kidney cancer	1.68e-05	0.000285	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ITPR2—kidney cancer	1.67e-05	0.000283	CbGpPWpGaD
Pemetrexed—Diarrhoea—Doxorubicin—kidney cancer	1.66e-05	0.000138	CcSEcCtD
Pemetrexed—DHFR—Metabolism—SCARB1—kidney cancer	1.65e-05	0.00028	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS1—kidney cancer	1.63e-05	0.000277	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PSMD7—kidney cancer	1.6e-05	0.000272	CbGpPWpGaD
Pemetrexed—Dizziness—Doxorubicin—kidney cancer	1.6e-05	0.000134	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—CDKN2A—kidney cancer	1.56e-05	0.000265	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1B—kidney cancer	1.54e-05	0.000262	CbGpPWpGaD
Pemetrexed—Vomiting—Doxorubicin—kidney cancer	1.54e-05	0.000128	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—kidney cancer	1.53e-05	0.000127	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—kidney cancer	1.52e-05	0.000127	CcSEcCtD
Pemetrexed—TYMS—Metabolism—GSTT1—kidney cancer	1.52e-05	0.000258	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ACHE—kidney cancer	1.52e-05	0.000258	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—kidney cancer	1.52e-05	0.000258	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—BCHE—kidney cancer	1.52e-05	0.000258	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTP1—kidney cancer	1.5e-05	0.000255	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC5A5—kidney cancer	1.5e-05	0.000255	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—kidney cancer	1.5e-05	0.000255	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—kidney cancer	1.47e-05	0.00025	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—POMC—kidney cancer	1.46e-05	0.000249	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC2A1—kidney cancer	1.45e-05	0.000246	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—RAF1—kidney cancer	1.44e-05	0.000245	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SCARB1—kidney cancer	1.44e-05	0.000245	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—kidney cancer	1.44e-05	0.00012	CcSEcCtD
Pemetrexed—SLC46A1—Disease—ERBB2—kidney cancer	1.43e-05	0.000242	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS1—kidney cancer	1.43e-05	0.000242	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ABCB1—kidney cancer	1.42e-05	0.000242	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MTOR—kidney cancer	1.41e-05	0.000239	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CD4—kidney cancer	1.4e-05	0.000239	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN2B—kidney cancer	1.4e-05	0.000237	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PSMD7—kidney cancer	1.4e-05	0.000237	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—kidney cancer	1.39e-05	0.000237	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTM1—kidney cancer	1.38e-05	0.000235	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1B—kidney cancer	1.38e-05	0.000234	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2A—kidney cancer	1.36e-05	0.000231	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1B—kidney cancer	1.35e-05	0.000229	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—kidney cancer	1.33e-05	0.000226	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—BCHE—kidney cancer	1.33e-05	0.000225	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1B—kidney cancer	1.32e-05	0.000224	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—kidney cancer	1.32e-05	0.000224	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP1A1—kidney cancer	1.31e-05	0.000222	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC5A5—kidney cancer	1.31e-05	0.000222	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTEN—kidney cancer	1.31e-05	0.000222	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—kidney cancer	1.28e-05	0.000218	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC2A1—kidney cancer	1.26e-05	0.000215	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—kidney cancer	1.25e-05	0.000212	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—kidney cancer	1.22e-05	0.000207	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.21e-05	0.000206	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTP1—kidney cancer	1.21e-05	0.000205	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1B—kidney cancer	1.2e-05	0.000205	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—kidney cancer	1.18e-05	0.000201	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—kidney cancer	1.17e-05	0.000198	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.16e-05	0.000196	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—kidney cancer	1.15e-05	0.000195	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ABCB1—kidney cancer	1.14e-05	0.000194	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HIF1A—kidney cancer	1.12e-05	0.00019	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TSC2—kidney cancer	1.11e-05	0.000189	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTM1—kidney cancer	1.11e-05	0.000189	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MAPK3—kidney cancer	1.09e-05	0.000184	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.06e-05	0.00018	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—kidney cancer	1.06e-05	0.000179	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTP1—kidney cancer	1.05e-05	0.000179	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP1A1—kidney cancer	1.05e-05	0.000179	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAPK3—kidney cancer	1.04e-05	0.000176	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MAPK1—kidney cancer	1.03e-05	0.000175	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—kidney cancer	1.03e-05	0.000175	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—kidney cancer	1.02e-05	0.000173	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—kidney cancer	1.01e-05	0.000172	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.01e-05	0.000171	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ABCB1—kidney cancer	9.98e-06	0.00017	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MAPK1—kidney cancer	9.88e-06	0.000168	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KIT—kidney cancer	9.84e-06	0.000167	CbGpPWpGaD
Pemetrexed—DHFR—Disease—APC—kidney cancer	9.84e-06	0.000167	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—POMC—kidney cancer	9.77e-06	0.000166	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTM1—kidney cancer	9.69e-06	0.000165	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MAPK3—kidney cancer	9.47e-06	0.000161	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—kidney cancer	9.34e-06	0.000159	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BRAF—kidney cancer	9.25e-06	0.000157	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—kidney cancer	9.22e-06	0.000157	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—kidney cancer	9.21e-06	0.000157	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP1A1—kidney cancer	9.18e-06	0.000156	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MAPK1—kidney cancer	9.01e-06	0.000153	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—kidney cancer	8.67e-06	0.000147	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—kidney cancer	8.58e-06	0.000146	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—POMC—kidney cancer	7.85e-06	0.000133	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—kidney cancer	7.79e-06	0.000132	CbGpPWpGaD
Pemetrexed—DHFR—Disease—RAF1—kidney cancer	7.73e-06	0.000131	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERBB2—kidney cancer	7.64e-06	0.00013	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—kidney cancer	7.57e-06	0.000129	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MTOR—kidney cancer	7.54e-06	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CD4—kidney cancer	7.53e-06	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—kidney cancer	7.47e-06	0.000127	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—kidney cancer	7.18e-06	0.000122	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1B—kidney cancer	7.08e-06	0.00012	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—POMC—kidney cancer	6.85e-06	0.000116	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—kidney cancer	6.79e-06	0.000115	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—kidney cancer	6.69e-06	0.000114	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—kidney cancer	6.52e-06	0.000111	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—kidney cancer	6.26e-06	0.000106	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAPK3—kidney cancer	5.57e-06	9.46e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—kidney cancer	5.46e-06	9.28e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—kidney cancer	5.46e-06	9.27e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—kidney cancer	5.42e-06	9.2e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MAPK1—kidney cancer	5.3e-06	9e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—kidney cancer	5.01e-06	8.5e-05	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—kidney cancer	4.79e-06	8.14e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—kidney cancer	4.76e-06	8.09e-05	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—kidney cancer	4.6e-06	7.81e-05	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—kidney cancer	3.85e-06	6.54e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—kidney cancer	3.36e-06	5.71e-05	CbGpPWpGaD
